Method for the treatment of polycystic kidney disease
AssigneeWyeth
InventorPhilip Frost
Life of this patent
Estimating the term…
Abstract
The present invention provides a method for treating, inhibiting the progression of, or eradicating polycystic kidney disease of in a patient in need thereof which comprises providing to said patient an effective amount of a TACE inhibitor compound in combination with an effective amount of a Src kinase inhibitor, a HER-2 kinase inhibitor, or a combination of Src and HER-2 inhibitor.
Claims26
A method for treating, inhibiting the progression of, or eradicating polycystic kidney disease in a mammal in need thereof which comprises providing to said mammal an effective amount of a TACE inhibitor compound in combination with a Src inhibitor, a HER-2 inhibitor or a combination of Src inhibitor and HER-2 inhibitor.
A method for treating, inhibiting the progression of, or eradicating polycystic kidney disease in a mammal in need thereof which comprises providing to said mammal an effective amount of a combination of a Src inhibiting compound and a HER-2 inhibiting compound.
A method for treating, inhibiting the progression of, or eradicating polycystic kidney disease in a mammal in need thereof which comprises providing to said mammal an effective amount of a Src inhibiting compound.
A method for treating, inhibiting the progression of, or eradicating polycystic kidney disease in a mammal in need thereof which comprises providing to said mammal an effective amount of a HER-2 inhibiting compound.
A method for treating, inhibiting the progression of, or eradicating polycystic kidney disease in a mammal in need thereof which comprises providing to said mammal an effective amount of a Src inhibiting compound.
A method for treating, inhibiting the progression of, or eradicating polycystic kidney disease in a mammal in need thereof which comprises providing to said mammal an effective amount of a HER-2 inhibiting compound.
A product comprising a TACE inhibitor compound and (i) a Src inhibitor or (ii) a HER-2 inhibitor;
- or (iii) a Src inhibitor and a HER-2 inhibitor
- as a combined preparation for simultaneous, separate or sequential use in treating, inhibiting the progression of, or eradicating polycystic kidney disease in a mammal.
A pharmaceutical composition for treating, inhibiting the progression, or eradicating polycystic kidney disease in a mammal comprising a TACE inhibitor compound and (i) a Src inhibitor or (ii) a HER-2 inhibitor;
- or (iii) a Src inhibitor and a HER-2 inhibitor, and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.